Verona Pharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 08, 2024 02:00 ET
|
Verona Pharma plc
OhtuvayreTM (ensifentrine) now available; patient shipments started Strong balance sheet supports commercialization and pipeline expansion Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST ...
Verona Pharma to Present at 44th Annual Canaccord Growth Conference
July 30, 2024 02:00 ET
|
Verona Pharma plc
LONDON and RALEIGH, N.C., July 30, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at...
Verona Pharma to Report Second Quarter 2024 Financial Results and Provide Corporate Update
July 25, 2024 02:00 ET
|
Verona Pharma plc
LONDON and RALEIGH, N.C., July 25, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the second...
Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)
June 26, 2024 16:57 ET
|
Verona Pharma plc
Verona Pharma announces the FDA approved Ohtuvayre (ensifentrine) for the maintenance treatment of COPD in adult patients.
Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 09, 2024 07:15 ET
|
Verona Pharma plc
PDUFA Target Action Date for Ensifentrine of June 26, 2024 Finalizing commercial launch preparations Strong balance sheet supports commercialization and pipeline expansion Conference call today at...
Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS
May 09, 2024 07:00 ET
|
Verona Pharma plc
Non-dilutive funding will support planned US commercial launch and expansion of ensifentrine’s clinical activities Cash runway extended beyond 2026 LONDON and RALEIGH, N.C., May 09, 2024 (GLOBE...
Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024
May 02, 2024 02:00 ET
|
Verona Pharma plc
Verona Pharma plc to present additional analyses of positive Phase 3 ENHANCE studies in COPD at ATS 2024.
Verona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate Update
April 25, 2024 02:00 ET
|
Verona Pharma plc
LONDON and RALEIGH, N.C., April 25, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the first...
Andrew Fisher Joins Verona Pharma as General Counsel
March 04, 2024 02:00 ET
|
Verona Pharma plc
Verona Pharma announces Mr. Andrew Fisher has today joined the Company as General Counsel, and member of the Executive Management Team.
Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
February 29, 2024 02:00 ET
|
Verona Pharma plc
PDUFA Target Action Date for ensifentrine of June 26, 2024 Commercialization preparations advance Strong balance sheet supports commercialization and Company's growth Conference call today at 9:00...